CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials

Experience of the GCIG CALYPSO trial

J. Alexandre, C. Brown, D. Coeffic, N. Raban, J. Pfisterer, J. Mäenpää, H. Chalchal, B. Fitzharris, B. Volgger, I. Vergote, C. Pisano, A. Ferrero, E. Pujade-Lauraine

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

BACKGROUND: CA-125 as a tumour progression criterion in relapsing ovarian cancer (ROC) trials remains controversial. CALYPSO is a large randomised trial incorporating CA-125 (GCIG criteria) and symptomatic deterioration in addition to Response Evaluation Criteria in Solid Tumours (RECIST) criteria (radiological) to determine progression. METHODS: In all, 976 patients with platinum-sensitive ROC were randomised to carboplatin-paclitaxel (C-P) or carboplatin-pegylated liposomal doxorubicin (C-PLD). CT-scan and CA-125 were performed every 3 months until progression. RESULTS: In all, 832 patients (85%) progressed, with 60% experiencing a first radiological progression, 10% symptomatic progression, and 28% CA-125 progression without evidence of radiological or symptomatic progression. The benefit of C-PLD vs C-P in progression-free survival was not influenced by type of first progression (hazard ratio 0.85 (95% confidence interval (CI): 0.66-1.10) and 0.84 (95% CI: 0.72-0.98) for CA-125 and RECIST, respectively). In patients with CA-125 first progression who subsequently progressed radiologically, a delay of 2.3 months was observed between the two progression types. After CA-125 first progression, median time to new treatment was 2.0 months. In all, 81%of the patients with CA-125 or radiological first progression and 60% with symptomatic first progression received subsequent treatment. CONCLUSION: CA-125 and radiological tests performed similarly in determining progression with C-PLD or C-P. Additional follow-up with CA-125 measurements was not associated with overtreatment.

Original languageEnglish
Pages (from-to)633-637
Number of pages5
JournalBritish Journal of Cancer
Volume106
Issue number4
DOIs
Publication statusPublished - Feb 14 2012

Fingerprint

Carboplatin
Ovarian Neoplasms
Neoplasms
Paclitaxel
Confidence Intervals
Platinum
Disease-Free Survival
Therapeutics
liposomal doxorubicin
Response Evaluation Criteria in Solid Tumors

Keywords

  • CA-125
  • carboplatin
  • ovarian cancer
  • paclitaxel
  • pegylated liposomal doxorubicin
  • radiological

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Alexandre, J., Brown, C., Coeffic, D., Raban, N., Pfisterer, J., Mäenpää, J., ... Pujade-Lauraine, E. (2012). CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: Experience of the GCIG CALYPSO trial. British Journal of Cancer, 106(4), 633-637. https://doi.org/10.1038/bjc.2011.593

CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials : Experience of the GCIG CALYPSO trial. / Alexandre, J.; Brown, C.; Coeffic, D.; Raban, N.; Pfisterer, J.; Mäenpää, J.; Chalchal, H.; Fitzharris, B.; Volgger, B.; Vergote, I.; Pisano, C.; Ferrero, A.; Pujade-Lauraine, E.

In: British Journal of Cancer, Vol. 106, No. 4, 14.02.2012, p. 633-637.

Research output: Contribution to journalArticle

Alexandre, J, Brown, C, Coeffic, D, Raban, N, Pfisterer, J, Mäenpää, J, Chalchal, H, Fitzharris, B, Volgger, B, Vergote, I, Pisano, C, Ferrero, A & Pujade-Lauraine, E 2012, 'CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: Experience of the GCIG CALYPSO trial', British Journal of Cancer, vol. 106, no. 4, pp. 633-637. https://doi.org/10.1038/bjc.2011.593
Alexandre, J. ; Brown, C. ; Coeffic, D. ; Raban, N. ; Pfisterer, J. ; Mäenpää, J. ; Chalchal, H. ; Fitzharris, B. ; Volgger, B. ; Vergote, I. ; Pisano, C. ; Ferrero, A. ; Pujade-Lauraine, E. / CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials : Experience of the GCIG CALYPSO trial. In: British Journal of Cancer. 2012 ; Vol. 106, No. 4. pp. 633-637.
@article{5b73e994edd649be9194dc966642bfed,
title = "CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: Experience of the GCIG CALYPSO trial",
abstract = "BACKGROUND: CA-125 as a tumour progression criterion in relapsing ovarian cancer (ROC) trials remains controversial. CALYPSO is a large randomised trial incorporating CA-125 (GCIG criteria) and symptomatic deterioration in addition to Response Evaluation Criteria in Solid Tumours (RECIST) criteria (radiological) to determine progression. METHODS: In all, 976 patients with platinum-sensitive ROC were randomised to carboplatin-paclitaxel (C-P) or carboplatin-pegylated liposomal doxorubicin (C-PLD). CT-scan and CA-125 were performed every 3 months until progression. RESULTS: In all, 832 patients (85{\%}) progressed, with 60{\%} experiencing a first radiological progression, 10{\%} symptomatic progression, and 28{\%} CA-125 progression without evidence of radiological or symptomatic progression. The benefit of C-PLD vs C-P in progression-free survival was not influenced by type of first progression (hazard ratio 0.85 (95{\%} confidence interval (CI): 0.66-1.10) and 0.84 (95{\%} CI: 0.72-0.98) for CA-125 and RECIST, respectively). In patients with CA-125 first progression who subsequently progressed radiologically, a delay of 2.3 months was observed between the two progression types. After CA-125 first progression, median time to new treatment was 2.0 months. In all, 81{\%}of the patients with CA-125 or radiological first progression and 60{\%} with symptomatic first progression received subsequent treatment. CONCLUSION: CA-125 and radiological tests performed similarly in determining progression with C-PLD or C-P. Additional follow-up with CA-125 measurements was not associated with overtreatment.",
keywords = "CA-125, carboplatin, ovarian cancer, paclitaxel, pegylated liposomal doxorubicin, radiological",
author = "J. Alexandre and C. Brown and D. Coeffic and N. Raban and J. Pfisterer and J. M{\"a}enp{\"a}{\"a} and H. Chalchal and B. Fitzharris and B. Volgger and I. Vergote and C. Pisano and A. Ferrero and E. Pujade-Lauraine",
year = "2012",
month = "2",
day = "14",
doi = "10.1038/bjc.2011.593",
language = "English",
volume = "106",
pages = "633--637",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials

T2 - Experience of the GCIG CALYPSO trial

AU - Alexandre, J.

AU - Brown, C.

AU - Coeffic, D.

AU - Raban, N.

AU - Pfisterer, J.

AU - Mäenpää, J.

AU - Chalchal, H.

AU - Fitzharris, B.

AU - Volgger, B.

AU - Vergote, I.

AU - Pisano, C.

AU - Ferrero, A.

AU - Pujade-Lauraine, E.

PY - 2012/2/14

Y1 - 2012/2/14

N2 - BACKGROUND: CA-125 as a tumour progression criterion in relapsing ovarian cancer (ROC) trials remains controversial. CALYPSO is a large randomised trial incorporating CA-125 (GCIG criteria) and symptomatic deterioration in addition to Response Evaluation Criteria in Solid Tumours (RECIST) criteria (radiological) to determine progression. METHODS: In all, 976 patients with platinum-sensitive ROC were randomised to carboplatin-paclitaxel (C-P) or carboplatin-pegylated liposomal doxorubicin (C-PLD). CT-scan and CA-125 were performed every 3 months until progression. RESULTS: In all, 832 patients (85%) progressed, with 60% experiencing a first radiological progression, 10% symptomatic progression, and 28% CA-125 progression without evidence of radiological or symptomatic progression. The benefit of C-PLD vs C-P in progression-free survival was not influenced by type of first progression (hazard ratio 0.85 (95% confidence interval (CI): 0.66-1.10) and 0.84 (95% CI: 0.72-0.98) for CA-125 and RECIST, respectively). In patients with CA-125 first progression who subsequently progressed radiologically, a delay of 2.3 months was observed between the two progression types. After CA-125 first progression, median time to new treatment was 2.0 months. In all, 81%of the patients with CA-125 or radiological first progression and 60% with symptomatic first progression received subsequent treatment. CONCLUSION: CA-125 and radiological tests performed similarly in determining progression with C-PLD or C-P. Additional follow-up with CA-125 measurements was not associated with overtreatment.

AB - BACKGROUND: CA-125 as a tumour progression criterion in relapsing ovarian cancer (ROC) trials remains controversial. CALYPSO is a large randomised trial incorporating CA-125 (GCIG criteria) and symptomatic deterioration in addition to Response Evaluation Criteria in Solid Tumours (RECIST) criteria (radiological) to determine progression. METHODS: In all, 976 patients with platinum-sensitive ROC were randomised to carboplatin-paclitaxel (C-P) or carboplatin-pegylated liposomal doxorubicin (C-PLD). CT-scan and CA-125 were performed every 3 months until progression. RESULTS: In all, 832 patients (85%) progressed, with 60% experiencing a first radiological progression, 10% symptomatic progression, and 28% CA-125 progression without evidence of radiological or symptomatic progression. The benefit of C-PLD vs C-P in progression-free survival was not influenced by type of first progression (hazard ratio 0.85 (95% confidence interval (CI): 0.66-1.10) and 0.84 (95% CI: 0.72-0.98) for CA-125 and RECIST, respectively). In patients with CA-125 first progression who subsequently progressed radiologically, a delay of 2.3 months was observed between the two progression types. After CA-125 first progression, median time to new treatment was 2.0 months. In all, 81%of the patients with CA-125 or radiological first progression and 60% with symptomatic first progression received subsequent treatment. CONCLUSION: CA-125 and radiological tests performed similarly in determining progression with C-PLD or C-P. Additional follow-up with CA-125 measurements was not associated with overtreatment.

KW - CA-125

KW - carboplatin

KW - ovarian cancer

KW - paclitaxel

KW - pegylated liposomal doxorubicin

KW - radiological

UR - http://www.scopus.com/inward/record.url?scp=84856840128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856840128&partnerID=8YFLogxK

U2 - 10.1038/bjc.2011.593

DO - 10.1038/bjc.2011.593

M3 - Article

VL - 106

SP - 633

EP - 637

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -